about
Chemoresistance and targeted therapies in ovarian and endometrial cancersPost-translational regulation of the cleaved fragment of Par-4 in ovarian and endometrial cancer cells.Inhibitory effect of Par-4 combined with cisplatin on human Wilms' tumor cells.Circulating GRP78 antibodies from ovarian cancer patients: a promising tool for cancer cell targeting drug delivery system?Recombinant Production and Characterization of SAC, the Core Domain of Par-4, by SUMO Fusion System.
P2860
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Role of PAR-4 in ovarian cancer.
@ast
Role of PAR-4 in ovarian cancer.
@en
type
label
Role of PAR-4 in ovarian cancer.
@ast
Role of PAR-4 in ovarian cancer.
@en
prefLabel
Role of PAR-4 in ovarian cancer.
@ast
Role of PAR-4 in ovarian cancer.
@en
P2093
P2860
P356
P1433
P1476
Role of PAR-4 in ovarian cancer.
@en
P2093
Florence Delie
Jean-Christophe Tille
Marianne Kramer
Marie Cohen
Pascale Ribaux
Patrick Petignat
Sonia Meynier
P2860
P304
22641-22652
P356
10.18632/ONCOTARGET.4010
P407
P577
2015-05-27T00:00:00Z